Allergy Diagnostics Global Market Report 2024

An allergy is the immune system's reaction to an allergen, a substance that is typically harmless to the human body. Allergens can include various foreign substances like certain foods (peanuts, milk, eggs, and wheat), pollen, and pet dander. Allergy diagnostics is a process conducted by qualified allergy specialists to assess whether the body is allergic to a particular substance.

The main types of allergy diagnostics tests are in-vivo allergy tests, which are performed on the human body to identify the cause of allergic reactions, and in-vitro allergy tests, which are conducted in laboratories using test tubes and Petri dishes to identify allergy-causing substances. Products in the allergy diagnostics market include consumables, instruments, and luminometers. Allergens are categorized into inhaled allergens, food allergens, and drug allergens. Major end-users of allergy diagnostics include diagnostic laboratories, hospital-based laboratories, and academic and research institutes.

The allergy diagnostics market research report is one of a series of new reports that provides allergy diagnostics market statistics, including allergy diagnostics industry global market size, regional shares, competitors with an allergy diagnostics market share, detailed allergy diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the allergy diagnostics industry. This allergy diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The allergy diagnostics market size has grown rapidly in recent years. It will grow from $5.77 billion in 2023 to $6.48 billion in 2024 at a compound annual growth rate (CAGR) of 12.3%. The growth observed in the historical period can be attributed to factors such as the increased prevalence of allergies, investments in research and development of allergy diagnostics, changes in dietary habits and environmental factors, government initiatives, and a rise in demand for personalized medicine.

The allergy diagnostics market size is expected to see rapid growth in the next few years. It will grow to $10.4 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The anticipated growth in the forecast period can be attributed to factors such as economic growth, the expansion of healthcare infrastructure, the increase in the aging population, and a greater emphasis on early diagnosis and prevention in healthcare. Key trends expected in this forecast period include advancements in molecular allergy diagnostics, the development of customized allergen profiles, the availability of allergy testing kits for home use, the integration of artificial intelligence (AI) in allergy diagnostics, and the rise of telemedicine and remote allergy consultations.

The increasing incidence of allergic diseases is set to drive the expansion of the allergy diagnostics market. The uptick in allergic disorders is linked to amplified environmental pollution arising from various sources such as heavy traffic and industrial emissions. Allergic reactions are adverse immune responses triggered by allergens, leading to conditions like allergic rhinitis, food allergies, skin allergies, and asthma. The primary remedy for these conditions involves avoiding exposure to the allergen, making precise allergy diagnostics an integral part of effective treatment. As per the American College of Allergy, Asthma, and Immunology (ACAAI), the prevalence of allergic diseases is considerable in the United States across all age groups, affecting millions. Asthma, affecting about 24 million individuals, including over 6 million children, and allergies impacting more than 50 million Americans annually. The economic burden from allergies is substantial, costing about $18 million in excess.

The enhancement of healthcare infrastructure is anticipated to be a driving force behind the growth of the allergy diagnostics market. Healthcare infrastructure encompasses the complete network of healthcare services and resources available in a specific region or country. This infrastructure enables access to specialized allergy clinics, diagnostics facilities, and expert healthcare practitioners skilled in diagnosing allergic conditions. This system ensures timely and accurate evaluations for individuals dealing with allergy-related concerns. As of May 2023, the Office for National Statistics reports a significant increase in healthcare spending in the UK, which saw a real-term expenditure hike of about 13.5% (£32 billion) ($38.78 billion) and a nominal-term increase of roughly 26.8% (£60 billion) ($72.72 billion) compared to 2019. This notable investment in healthcare infrastructure underlines its vital role in fostering the growth of allergy diagnostics.

A recent trend observed in the allergy diagnostics market is the rise in collaborations and partnerships between companies to develop innovative testing techniques or enhance existing methodologies. An example from August 2022 includes LifeMD, a US-based telehealth company, revealing a strategic partnership between its subsidiary, Cleared, and Allergenis, a US-based predictive data analytics company. This collaboration is designed to leverage Cleared's expertise in allergy telehealth services and Allergenis' peanut allergy diagnostic blood test within the direct-to-customer channel. This trend of strategic partnerships is aimed at mutual innovation and improvement of diagnostic solutions in the allergy diagnostics industry.

Major firms within the allergy diagnostics sector are pioneering cutting-edge technologies like an AI-fueled allergy component testing platform to enhance their market position and drive profitability. An AI-powered allergy component testing platform utilizes advanced artificial intelligence to interpret allergy testing outcomes. For example, in May 2023, Metropolis, an India-based pathology lab and diagnostic center, introduced an AI-driven allergy component testing platform capable of identifying various allergens like respiratory, contact, and food-related. This innovative platform yields detailed insights into individual allergy conditions, facilitating more informed clinical decisions through component-resolved diagnostics (CRD) and AI-enabled analysis.

In October 2021, IMA Group, a network of integrated clinical research sites specializing in Phase II-IV clinical trials, disclosed its acquisition of Diagnostics Research Group (DXRG) for an undisclosed sum. This strategic move allowed IMA to broaden its reach across patient populations and establish a stronger presence in the southwestern United States. The acquisition bolstered IMA's Clinical Research Division, expanding its network to over 90 medical offices and reinforcing its expertise in vaccine and medical device development, internal medicine, allergies, pulmonary diseases, and fatty liver conditions.

Major companies operating in the allergy diagnostics market include BioMerieux SA, Danaher Corporation, HOB Biotech Group Corp. Ltd., HYCOR Biomedical, Lincoln Diagnostics Inc., Omega Diagnostics Group PLC., Siemens Healthineers AG, Thermo Fisher Scientific Inc., PerkinElmer Inc., R-Biopharm AG, Alcon Laboratories Inc., Abbott Laboratories, HollisterStier Allergy, NEOGEN Corporation, AESKU.GROUP GmbH, ACON Laboratories Inc., Erba Group, Astra Biotech GmbH, Stallergenes Greer, Hitachi Chemical Co. Ltd., Minaris Medical America Inc., Diagenics Limited, DST Diagnostische Systeme & Technologien GmbH, HAL Allergy Group, INDOOR Biotechnologies Inc., MacroArray Technologies LLC, Microtest Laboratories Inc., Phadia AB, Quest Diagnostics, Randox Laboratories Ltd., Symbiotix Biotherapies Inc., Eurofins Viracor Inc., VRL Laboratories

North America was the largest region in the allergy diagnostics market in 2023. The regions covered in the allergy diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the allergy diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The allergy diagnostics market includes revenue earned by instruments such as immunoassay analyzers, ELISA analyzers, luminometers, and other instruments that are used to diagnose allergies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.